The largest psychiatric safety meta-analysis to date found that GLP-1 medications were not associated with increased risk of serious psychiatric adverse events overall ( Pierret et al., JAMA Psychiatry, 2025 ), and a post-hoc analysis of the major semaglutide weight management trials found no differences in depression, suicidal ideation, or suicidal behavior compared to placebo ( Wadden et al., JAMA Internal Medicine, 2024 )
Consumers should seek independent clinical advice before investing in such products and consult resources such as NICE Clinical Knowledge Summaries, the British Association of Dermatologists (BAD), and the Primary Care Dermatology Society (PCDS) for up-to-date, evidence-based guidance on hair loss management
The researchers are planning a randomized trial to test whether benefits extend beyond weight to cardiovascular and metabolic markers
Can I switch from PeterMD semaglutide to PeterMD tirzepatide
These symptoms are generally mild to moderate in severity and tend to diminish over time as physiologic adaptation occurs